Semaglutide
Also known as: Semaglutide (GLP-1 agonist)
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Who's worth your money for Semaglutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 15 scored sellers
$976 · 200mg · 99.9% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 10mg
Most tested
12 independent COAs on file
$130 · 20mg · 99.3% purity
Average price
$6.77/mg
Sellers
25
45-day trend
+3.2%
21 of 25 sellers have a current price· 4 stale hidden· 2 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 5d ago · stale
$4.88/mg -27.9% vs avg$976
200mg
- 🇺🇸 Hydro Research Peptides97
via Disclosed Labs · 5d ago · stale
$9.80/mg +44.8% vs avg$490
50mg
- 🇺🇸 Prime Peptides96
✓ verified at source · 1h ago
$3.50/mg -48.3% vs avg$70.00
20mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 5d ago · stale
$6.50/mg -3.9% vs avg$130
20mg
- Nova Peptides94
via Disclosed Labs · 5d ago · stale
$8.00/mg +18.2% vs avg$79.99
10mg
no purity - 🇺🇸 Polaris Peptides89
✓ verified at source · 1h ago
$9.00/mg +33% vs avg$90.00
10mg
- optimasupply.is86
via Disclosed Labs · 5d ago · stale
$9.50/mg +40.4% vs avg$94.99
10mg
- 🇨🇳 Reta Peptide83
✓ verified at source · just now
$6.50/mg -3.9% vs avg$65.00
10mg
- Modern Research Peptides82
via Disclosed Labs · 5d ago · stale
$1.83/mg -72.9% vs avg$54.99
30mg
no purity - True Peptide82
via Disclosed Labs · 5d ago · stale
$4.00/mg -40.9% vs avg$120
30mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Semaglutide
Get one email when the market actually moves — no newsletter, no noise.
About Semaglutide
CAS
910463-68-2
Molecular formula
C187H291N45O59
Typical dose range
0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks
Half-life
~7 days
COAs for Semaglutide
195 third-party tests across 30 vendors. Each card links to the full report.
For
Semaglutide
by VoriLabs· batch SEMA_2608-A
For
Semaglutide
by Velora Biolabs· batch VBL-SM20-1
For
Semaglutide
by Peptide Plugs· batch 189-02-DK
For
Semaglutide
by VoriLabs· batch VoriLabs SEMA-2607-C
For
Semaglutide
by VoriLabs· batch VoriLabs SEMA-2607-B
For
Semaglutide
by EZ Peptides· batch EZP-1P1007112026-04
For
Semaglutide
by Synthesis Peptides· batch 1G10826
For
Semaglutide
by Hydro Research Peptides· batch HR-2026-7341
For
Semaglutide
by Longeva· batch B-2026-SEMA-5-001
For
Semaglutide
by Peptide Partners· batch SPL-4149
For
Semaglutide
by Peptide Plugs· batch 125-01-SM
For
Semaglutide
by Soma Peptides· batch SEV052657
For
Semaglutide
by Certified Peptides· batch 260518SG53
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by Blank Peptides· batch GS10-052026-4
For
Semaglutide
by Pepsgpt· batch P-2885342-P
For
Semaglutide
by Prime Peptides· batch 3022026SM
For
Semaglutide
by Prime Peptides· batch 3142026SM
For
Semaglutide
by Prime Peptides· batch 2242026SM
For
ION-1S
by Ion Peptide· batch ION1S20-04172026
For
Semaglutide
by Vertex Labs· batch SM0000038
For
Semaglutide
by OROS Research· batch OR-LPGLPS10-426-B3
For
Semaglutide
by Prime Peptides· batch 3272026SM
23 citations indexed for Semaglutide
Study · 2026
EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy
Adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are at risk for cardiometabolic complications and major adverse liver-related outcomes (MALO), including cirrhosis, cancer, and liver transplantation.
Study · 2026
Oral Semaglutide and the Kidney: Promise, Limitations, and the Road Ahead
cohort · 2026
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness.
Study · 2026
Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial
Introduction People with type 2 diabetes (T2D) and chronic kidney disease (CKD) often experience medication intolerance and side effects that worsen with lower estimated glomerular filtration rate (eGFR). This prespecified secondary analysis assessed the safety of semaglutide by baseline eGFR.
animal · 2026
Mechanistic benchmarking of SNAC, DDM, and LLC reveals enhancer-dependent pathways for intestinal semaglutide delivery
The oral delivery of peptide therapeutics remains constrained by poor intestinal permeability and the challenge of enhancing epithelial transport without compromising mucosal integrity.
Study · 2026
The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment
Objective This study aimed to evaluate the conventional and distributional cost-effectiveness of semaglutide, laparoscopic sleeve gastrectomy (LSG), and a "do nothing" option in Black and White racial subgroups.